-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec's content team On November 3, 2021, Antios Therapeutics announced the completion of a US$75 million B-1 round of financing to develop innovative therapies for functional cures of chronic hepatitis B virus (HBV) infection
.
The proceeds will be used to advance the clinical development of Antios' main drug candidate, ATI-2173, which is in phase 2b clinical trials
.
The press release pointed out that ATI-2173 is an active site polymerase inhibitor nucleotide (ASPIN).
Once approved, it is expected to become the cornerstone of a curative HBV treatment plan.
Its mechanism of action is similar to other methods for seeking a functional cure.
Complement each other
.
ATI-2173 is a new type of oral ASPIN molecule designed to deliver the 5'-monophosphate of clevudine to the liver
.
This molecule has potent anti-HBV activity and can maintain the inhibition of HBV DNA levels after drug withdrawal
.
ATI-2173 targets the liver, delivering high levels of drugs while limiting its systemic side effects
.
▲ATI-2173 can continue to maintain the inhibition of HBV DNA level after stopping the drug (picture source: Antios official website) So far, ATI-2173 alone or with tenofovir disoproxil fumarate (TDF) The preclinical data of the combined use show that it has the ability to continuously suppress HBV DNA levels
.
Moreover, early clinical trial results showed that after 28 days of ATI-2173 medication, even if the medication is stopped, the patient's HBV DNA level can be maintained for a long time without rebound
.
One of the patients had sustained virological response (SVR) for up to 6 months
.
Antios CEO Mr.
Greg Mayes said: "This round of financing allows us to accelerate the phase 2b clinical development of ATI-2173.
In our phase 1b study on HBV patients, ATI-2173 has proven its effective therapeutic effect.
, And long-lasting effects after discontinuation, and the overall drug is well tolerated
.
"Reference: [1] Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV.
Retrieved November 3, 2021, from https:// htmlDisclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
.
The proceeds will be used to advance the clinical development of Antios' main drug candidate, ATI-2173, which is in phase 2b clinical trials
.
The press release pointed out that ATI-2173 is an active site polymerase inhibitor nucleotide (ASPIN).
Once approved, it is expected to become the cornerstone of a curative HBV treatment plan.
Its mechanism of action is similar to other methods for seeking a functional cure.
Complement each other
.
ATI-2173 is a new type of oral ASPIN molecule designed to deliver the 5'-monophosphate of clevudine to the liver
.
This molecule has potent anti-HBV activity and can maintain the inhibition of HBV DNA levels after drug withdrawal
.
ATI-2173 targets the liver, delivering high levels of drugs while limiting its systemic side effects
.
▲ATI-2173 can continue to maintain the inhibition of HBV DNA level after stopping the drug (picture source: Antios official website) So far, ATI-2173 alone or with tenofovir disoproxil fumarate (TDF) The preclinical data of the combined use show that it has the ability to continuously suppress HBV DNA levels
.
Moreover, early clinical trial results showed that after 28 days of ATI-2173 medication, even if the medication is stopped, the patient's HBV DNA level can be maintained for a long time without rebound
.
One of the patients had sustained virological response (SVR) for up to 6 months
.
Antios CEO Mr.
Greg Mayes said: "This round of financing allows us to accelerate the phase 2b clinical development of ATI-2173.
In our phase 1b study on HBV patients, ATI-2173 has proven its effective therapeutic effect.
, And long-lasting effects after discontinuation, and the overall drug is well tolerated
.
"Reference: [1] Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV.
Retrieved November 3, 2021, from https:// htmlDisclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
